Category: Symptoms

Insomnia is one of the most common and most exhausting symptoms of benzodiazepine withdrawal. Patients who tolerated their original anxiety or sleep complaint relatively well now find themselves staring at the ceiling for entire nights, awake at three in the morning with their nervous system in full alert, or sleeping in two-hour increments that produce no real rest. The fatigue compounds across days. Cognitive function deteriorates. Patience erodes. Other withdrawal symptoms intensify because the nervous system never gets the chance to reset overnight that healthy sleep would have provided.

Sleep is one of the hardest aspects of benzodiazepine recovery, and it is one of the most poorly addressed by conventional approaches. Understanding what is happening in the sleeping brain during withdrawal, and what can and cannot be done about it, is part of getting through this phase without making the situation worse.

Why the Brain Forgets How to Sleep

Sleep is regulated by a complex interaction between several neurotransmitter systems, and GABA is one of the central players. The transition from wakefulness to sleep depends in part on rising GABA-mediated inhibition that quiets the cortex, allows the body to relax, and permits the cascade of neurochemical changes that produce sleep architecture. Benzodiazepines, which act on the GABA-A receptor, support this transition pharmacologically. Long-term use, however, leads to receptor adaptation. The body begins to rely on the medication to produce the inhibitory tone that initiates sleep, and the system’s own capacity to do this work atrophies.

When the medication is reduced or removed, the brain’s own sleep-initiating machinery has to come back online. This recovery is slow. The receptor adaptation that took months or years to develop does not reverse on a timescale that is comfortable for the patient. In the meantime, the patient is left with a nervous system that no longer remembers how to descend into sleep on its own.

This is what patients mean when they describe forgetting how to sleep. It is not metaphorical. The actual neurological process of falling asleep has been impaired, and it takes time to rebuild.

The Different Patterns of Withdrawal Insomnia

Withdrawal insomnia does not present uniformly. Several patterns are common, sometimes appearing in the same patient at different points in the taper.

Sleep onset insomnia. The patient lies in bed for hours, often into the early morning, unable to make the transition into sleep. The body is exhausted but the nervous system will not allow descent. This pattern is most common early in the taper or after a recent dose reduction.

Sleep maintenance insomnia. The patient falls asleep without major difficulty but wakes after one or two hours and cannot return to sleep. The early-morning awakening, often around three or four in the morning, becomes a recurring pattern. This is one of the most common features of benzodiazepine withdrawal and one of the most frustrating, because the patient does not even get the partial rest of the falling-asleep difficulty.

Fragmented sleep. The patient appears to sleep for multiple hours but awakens repeatedly, sometimes a dozen times a night, often without remembering each awakening clearly. The morning experience is one of having slept without resting.

Disturbed sleep architecture. Even when the total sleep time looks reasonable on paper, the proportions of light sleep, deep sleep, and REM sleep can be disrupted. Patients describe waking from what should have been sufficient sleep feeling unrefreshed, with vivid dreams or nightmares, or with a sense that the sleep was somehow not real.

Each pattern is driven by the same underlying receptor adaptation but reflects which part of the sleep cascade is most disrupted at a given moment. The patterns can shift over the course of a taper.

The Sleep Medication Trap

The natural impulse, when sleep collapses, is to reach for a sleep medication. For benzodiazepine patients in active taper, this is usually the wrong move, and several traps are worth recognizing.

Z-drugs such as zolpidem, eszopiclone, and zaleplon act on the same receptor system as benzodiazepines. Substituting a Z-drug for a benzodiazepine during taper is, from the receptor’s perspective, not really substituting at all. The patient may feel briefly better, but they are continuing to load the same system they are trying to unload. Many patients have ended up with a Z-drug dependence stacked on top of the benzodiazepine dependence they were trying to leave behind.

Trazodone, mirtazapine, and similar medications are sometimes used. These can produce sedation but each has its own complexities, and the response in benzodiazepine-injured patients is unpredictable. What helps one patient may worsen another. None of them addresses the underlying adaptation.

Antipsychotics such as quetiapine are frequently prescribed off-label for sleep. The risks of producing or worsening akathisia, of adding cognitive effects, and of creating a new dependence pattern make this a particularly difficult class for benzodiazepine patients. A patient who picks up a quetiapine prescription for sleep during a taper has often added a future tapering problem to their current one.

Antihistamines such as diphenhydramine, doxylamine, and hydroxyzine are sometimes used. These can be modestly helpful but rarely produce reliable sleep through the most difficult phases of withdrawal, and tolerance to their sedating effect tends to develop quickly with regular use.

The pattern across all of these is that no medication clean of the underlying problem reliably restores sleep during active benzodiazepine withdrawal. The goal during this phase is usually to support the patient through the difficulty without creating new dependencies.

What Can Help

The interventions that consistently make a small but real difference are not the ones that produce sleep on demand. They are the ones that support the recovering sleep system over time.

Maintaining a consistent wake time, even on nights with little or no sleep, gives the body’s circadian system a stable anchor. The temptation to sleep in after a poor night usually backfires because it shifts the circadian phase later. Getting up at the same time every morning is one of the most underrated supports for sleep recovery.

Morning light exposure, ideally outdoor light within the first hour of waking, sends a strong circadian signal that supports the evening drop into sleep. Even fifteen minutes outside in the morning can help over time.

Limiting evening light and screen exposure gives the system the dim signal it needs to begin shifting toward sleep. Bright bathroom lights, screens close to the face, and stimulating content all push against the natural drift toward rest.

Reducing or eliminating caffeine, particularly in the afternoon, can be more important than patients realize. The half-life of caffeine is long enough that an afternoon coffee can affect a sensitive nervous system at midnight.

Building a wind-down routine that the body can recognize as a sleep cue gives the recovering system something to respond to. The specifics are less important than the consistency. A predictable sequence of low-stimulation activities in the same order each night can over time reestablish the body’s pre-sleep state.

Cognitive behavioral therapy for insomnia, often abbreviated CBT-I, is the strongest non-medication approach available. It works by addressing the thoughts and behaviors that perpetuate insomnia, and it is increasingly accessible through telehealth and self-guided programs. For benzodiazepine patients with persistent insomnia, CBT-I is worth considering as a structured approach.

The Role of Patience

The hardest part of withdrawal insomnia is the timeline. The receptor adaptation that produced the dependence took months or years to develop. The recovery of natural sleep often takes months, sometimes longer. There is no intervention that compresses this timeline reliably. What helps is the willingness to support the system without forcing it, and to avoid interventions that may produce short-term sleep at long-term cost.

Patients who have come through severe withdrawal insomnia and out the other side describe the recovery as gradual. Sleep returns in pieces. A patient who has been getting two or three fragmented hours per night begins to get four. Then five. Then occasionally a night of seven hours that feels like a revelation. The improvement is not linear. There are setbacks. But the trajectory over months is real, and most patients eventually reach a stable sleep that approaches what they had before the medication years.

Reframing Insomnia as a Wave

One useful piece of cognitive work during withdrawal insomnia is to reframe it as a wave rather than a permanent state. A patient in the middle of a difficult sleep stretch can feel as though sleep is gone forever, that they will never sleep normally again. The lived experience of any single bad night supports that interpretation. The longer arc of recovery does not.

Holding the wave framing during the worst nights, even when it is not believed in the moment, helps patients endure. The night will end. The wave will pass. The next phase of recovery will continue. This is true even when it does not feel true.

The Clinical View

Dr. Leeds approaches insomnia in benzodiazepine patients as a symptom of the underlying receptor adaptation rather than a separate problem to medicate around. The most reliable path through is the path that supports the recovering sleep system without re-engaging the receptors the patient is trying to unload. This is harder than reaching for a sleep medication and gives the patient slower relief, but it preserves the trajectory of recovery and avoids creating new tapering problems for later.

Sleep does come back. The patient’s job during the worst stretches is to survive the nights, support the circadian system as best they can, and trust that the receptor work happening in the background is real, even when the night feels otherwise.

The stellate ganglion block, often abbreviated as SGB, is a procedure that has moved from a niche pain medicine intervention into wider clinical use over the past two decades. It is currently being explored as a possible tool for benzodiazepine withdrawal and BIND, particularly in patients whose dominant features point to a nervous system stuck in sympathetic overdrive. The evidence base in benzodiazepine patients specifically is limited, but the underlying mechanism is plausible enough that the procedure is worth understanding for any patient or clinician thinking about advanced options.

This is not a recommendation. It is a description of what SGB is, why it has come up in benzodiazepine circles, and what the procedure can and cannot reasonably be expected to do.

The Sympathetic Overdrive Picture

One of the most consistent features of benzodiazepine withdrawal and BIND is autonomic dysregulation, and within that broader picture, the dominant pattern is often sympathetic overdrive. The patient’s resting heart rate is elevated. Blood pressure can be labile. Body temperature does not stabilize. Sleep is disrupted by a system that cannot drop into a parasympathetic state. The patient describes a constant sense of being on alert, a low-grade fight-or-flight tone that does not match anything in the external environment.

This pattern reflects the loss of GABA-mediated inhibition that benzodiazepines were previously providing. With that inhibitory tone gone, sympathetic outflow runs at a higher set point than the body was running before the medication, and the parasympathetic system has lost its counterweight. The result is a nervous system that cannot find its way back to baseline through the usual self-regulating processes.

Many of the most distressing symptoms of advanced withdrawal can be traced back to this state. Akathisia, insomnia, autonomic instability, sensory hypersensitivity, and the sense of being unable to rest all share this sympathetic-overdrive thread. If a procedure could interrupt that pattern, even temporarily, it could in principle give the nervous system a window in which to settle.

What the Stellate Ganglion Block Does

The stellate ganglion is a cluster of sympathetic nerve cell bodies located in the lower neck, near the level of the sixth and seventh cervical vertebrae. It serves as a major relay point for sympathetic signaling to the head, neck, upper chest, and arms. An SGB is performed by injecting a local anesthetic around the ganglion, typically under ultrasound guidance, which temporarily blocks the sympathetic signals passing through that area.

The block itself takes only a few minutes and is performed in an outpatient setting. The local anesthetic effect lasts hours, but the proposed therapeutic effect can outlast the anesthetic. The hypothesis is that interrupting sympathetic outflow even briefly can reset the nervous system’s set point, allowing it to return to operation at a less hyperactive level.

How SGB Came to Be Considered

Stellate ganglion blocks have been used for decades in pain medicine, particularly for complex regional pain syndrome and certain neuropathic pain conditions involving the upper extremities. In the past fifteen years, the procedure has been studied for post-traumatic stress disorder, with reports that it can produce reductions in PTSD symptoms in a subset of patients. The mechanism is thought to involve resetting the autonomic nervous system in a way that quiets the overactive sympathetic signaling that drives many PTSD features.

Because the symptom pattern in benzodiazepine withdrawal and PTSD share certain features, particularly the persistent sympathetic activation, attention has turned to whether SGB might offer benefit in benzodiazepine-injured patients. Anecdotal reports from patients who have tried it range from no effect to substantial improvement, with most patients in the middle reporting some reduction in symptoms that may not be permanent.

What Patients Report After SGB

The pattern of patient reports is uneven, which is consistent with what is seen in PTSD work as well. Some patients describe noticeable calming within hours of the block, with reduced akathisia, easier sleep, and a sense that their nervous system has “let go” of a baseline tension they had not realized was there. Others report no meaningful change. A subset describes mild benefit that fades over days to weeks, leaving them considering a repeat block.

The patients most likely to report benefit appear to be those whose dominant symptoms map cleanly onto sympathetic overdrive: insomnia driven by inability to relax, akathisia, autonomic instability, and chronic muscle tension. Patients whose primary symptoms are different, such as cognitive fog, mood changes, or gastrointestinal disruption, tend to report less benefit.

Repeat blocks are sometimes used. The number of blocks needed, and the optimal interval between them, is not well defined for benzodiazepine patients. PTSD protocols often involve a series of two to four blocks over a period of weeks.

Where the Evidence Stands

The honest summary is that the evidence for SGB in benzodiazepine withdrawal specifically is limited to clinical reports and patient experience. The mechanism is biologically reasonable. The procedure has a long track record in other contexts. But controlled data in benzodiazepine-injured patients are not yet available in any meaningful volume.

This places SGB in the category of interventions that may be worth considering for selected patients, particularly when more conservative options have not produced enough relief, but should not be approached as a proven treatment. A patient considering SGB should go in with realistic expectations: it may help, it may not, and the response is difficult to predict in advance.

What to Consider Before SGB

Several factors are worth thinking through.

The procedure should be performed by a clinician experienced in ultrasound-guided SGB. The anatomy of the lower neck contains structures that need to be avoided, and operator experience matters.

The patient’s overall taper situation should be relatively stable. SGB during an acute, rapidly destabilizing phase of a taper is unlikely to produce the same results as SGB in a patient whose taper has been paused and whose symptom pattern has settled into a recognizable picture.

Medication interactions and pre-procedure planning are part of what the procedural team will manage. The benzodiazepine patient who is already on minimal medications and who is not in active withdrawal crisis is a more straightforward candidate than the patient with complex polypharmacy or active instability.

The financial picture should be addressed in advance. SGB performed for benzodiazepine withdrawal is not consistently covered by insurance, and out-of-pocket costs can be significant. The cost-to-likely-benefit calculation is part of the decision.

The Clinical View

Dr. Leeds approaches advanced interventions like SGB with the same framework he applies to other adjuncts: they are tools, not solutions, and the underlying work of slow, patient-centered tapering remains the foundation. SGB may have a place for selected patients whose symptom pattern is consistent with sympathetic overdrive, who have stabilized their taper, and who are ready for an intervention that may produce meaningful relief without guarantees.

For most patients, the highest-yield work is still the work that is hardest to articulate as a specific intervention: a careful taper rate, adequate time for the nervous system to settle between cuts, supportive medications used appropriately and not stacked indiscriminately, and an environment that does not amplify the symptom load. SGB sits alongside that work for some patients. It does not replace it for any of them.

Patients who are interested in the procedure should have a conversation with their tapering physician about whether the timing is right and whether the symptom pattern fits what SGB plausibly addresses. The procedure is not a turning point that converts a difficult taper into an easy one, but for the right patient, it may offer a window of relief that other interventions have not provided.

Akathisia is one of the most distressing experiences a person can have, and one of the least understood by clinicians who have not seen it in benzodiazepine patients. The word itself comes from a Greek root meaning “unable to sit,” but that translation does not capture what the experience actually feels like. Patients describe a relentless internal restlessness, a sense of needing to move that cannot be relieved by movement, a feeling of being driven from inside their own skin. It can produce pacing for hours, an inability to lie still, a sense that the body is being electrified, and a level of suffering that breaks down even patients who have weathered everything else withdrawal has thrown at them.

Akathisia is not a fringe symptom of benzodiazepine withdrawal. It is one of the symptoms patients fear most, and one of the symptoms that most often goes unrecognized when patients show up in emergency rooms or psychiatric offices looking for help. Understanding what akathisia is, why it happens during benzodiazepine withdrawal, and what does and does not help is essential for patients living with it and for the clinicians trying to support them.

What Akathisia Actually Is

Akathisia is a movement disorder, but the movement is the visible part of a deeper neurological state. The patient’s nervous system has shifted into a pattern of dysregulation that produces a continuous feeling of needing to move, combined with a continuous failure of movement to provide any relief. A person with simple anxiety paces because they are anxious. A person with akathisia paces because they cannot stop, and the pacing does not help.

The internal experience is what makes akathisia so difficult to convey. Patients describe it as restlessness multiplied many times over, as agitation that has no emotional cause, as a feeling of wanting to crawl out of their own body. Sleep becomes nearly impossible because lying still is intolerable. Sitting through a meal can feel like sitting on hot coals. Even the smallest tasks become exhausting because the body is constantly in motion or constantly demanding motion.

This experience is often mistaken for severe anxiety, and the two can coexist, but they are not the same. Anxiety responds to calming inputs. Akathisia does not. A patient with akathisia will tell you that nothing they have tried touches it, and they are usually correct.

Why Benzodiazepine Withdrawal Produces Akathisia

Benzodiazepines work primarily through GABA-A receptors, the main inhibitory system in the central nervous system. Long-term benzodiazepine use leads to receptor adaptation: the system becomes less responsive to the medication and to the body’s own GABA. When the medication is reduced or removed, the inhibitory tone that was being maintained pharmacologically is no longer available. The nervous system is left in a state of relative excitation that the body has not yet reorganized to handle.

That excitation does not show up uniformly. It manifests through whichever pathways are most vulnerable in the individual patient. In some patients it is sleep that breaks down. In others it is autonomic regulation. In others it is sensory processing. And in some, the pattern of dysregulation produces akathisia. The dopaminergic and adrenergic systems are involved, the GABAergic system is involved, and the result is a motor and sensory state that resembles the akathisia produced by certain antipsychotics, even though the trigger is entirely different.

The Misdiagnosis Problem

Patients with benzodiazepine-induced akathisia are routinely misdiagnosed. Emergency room clinicians, primary care physicians, and even psychiatrists who have not specifically encountered withdrawal-related akathisia often interpret the presentation as severe anxiety, agitated depression, or a panic state. The patient describes inability to sit still, racing internal feelings, and overwhelming distress. The diagnostic conclusion is usually that the patient needs more medication for their anxiety, not less.

This misreading drives some of the worst clinical decisions made for benzodiazepine patients. A patient with akathisia from benzodiazepine withdrawal who is given a higher dose of benzodiazepine may feel briefly better and then feel worse. A patient given an antipsychotic for what is interpreted as agitation may have their akathisia made dramatically worse, because antipsychotics can produce akathisia of their own through a different mechanism. The original problem is not addressed, and the medication response often adds new layers of suffering.

Recognizing akathisia for what it is, in the context of a benzodiazepine taper or a recent reduction, changes the entire treatment approach. The problem is not anxiety. The problem is a nervous system that has been pushed past what it can compensate for.

What Standard Responses Get Wrong

Several common clinical responses to akathisia during benzodiazepine withdrawal tend to make the situation worse rather than better.

Adding antipsychotics is one of the most damaging. Quetiapine, risperidone, olanzapine, and similar medications carry their own risk of producing akathisia. For a patient already in a withdrawal-related akathisia state, adding an antipsychotic can compound the problem. The patient ends up with two overlapping akathisias driven by different mechanisms, and the second one will not resolve until the antipsychotic is removed.

Increasing or reinstating benzodiazepines often produces partial relief that does not last. The dose needed to suppress the akathisia tends to climb. Reinstatement may be the right move for some patients in some contexts, but it is not a long-term solution for akathisia.

Pushing the taper forward through severe akathisia is rarely the answer. Many patients have been told to “stay the course” when their nervous system is signaling that the rate of reduction is more than it can manage. Continuing to cut while in active akathisia tends to deepen the problem.

What Can Help

The honest answer is that no medication reliably eliminates withdrawal-related akathisia. There are interventions that sometimes reduce the intensity, and there are strategies that help the patient survive the experience until time and a stabilized nervous system bring the akathisia down.

Slowing or pausing the taper is usually the first step. Akathisia often signals that the current rate of reduction is exceeding what the nervous system can absorb. Holding at the current dose, or even returning to a slightly higher prior dose, can give the system time to settle.

Physical strategies that some patients find partial relief in include cold water on the face or hands, weighted blankets, slow rhythmic movement that the patient chooses rather than being driven into, and time outdoors with the kind of low-stimulation environment that does not amplify the sensory load. None of these is a treatment. They are tools that may help a patient endure the hours and days while the underlying state slowly improves.

Beta blockers such as propranolol are sometimes used to reduce the adrenergic component, with mixed results. Hydroxyzine is sometimes useful at the margins. For some patients, a small amount of opioid analgesia produces relief that nothing else has touched, though this is rarely a sustainable approach. The most consistent finding is that there is no consistent answer, and patients respond differently.

The Role of Time

Akathisia driven by benzodiazepine withdrawal eventually subsides, but the time course is highly variable. Some patients see improvement within days of stabilizing the taper. Others live with significant akathisia for months. A subset of patients with protracted symptoms or BIND experience akathisia as a long-term feature that gradually softens over many months or years rather than weeks.

This is why the work of recognizing akathisia early and adjusting the taper accordingly matters so much. The longer a patient remains in active akathisia, the harder the recovery process becomes. Dr. Leeds approaches akathisia as a signal that something is wrong with the rate of reduction, not as a symptom to medicate around. The most effective response is usually the one that addresses the underlying destabilization, supports the patient through the difficult window, and avoids interventions that risk making the akathisia worse.

Patients who live through severe akathisia and come out the other side describe it as one of the most difficult experiences of their lives. The fact that it improves, and that patients do recover, is a piece of information worth holding on to during the worst of it.

Benzodiazepine withdrawal is usually discussed as what happens after the taper — the symptoms that emerge as the dose comes down. But a substantial number of long-term benzodiazepine patients are already in withdrawal while they are still taking their medication at the prescribed dose. This is tolerance withdrawal, and recognizing it matters clinically because it changes what the taper is actually doing.

The phenomenon is documented in the Ashton Manual and elsewhere in the benzodiazepine literature as the state in which the original therapeutic effect of the medication has been lost while the patient remains on it. The anxiety or insomnia that the benzodiazepine was originally prescribed for returns, often with new features, and the patient typically concludes — along with the prescriber — that the original condition has worsened and needs a higher dose. It has not necessarily worsened. The receptors have adapted.

How Tolerance Develops

GABA-A receptors are the inhibitory infrastructure of the central nervous system. Benzodiazepines act as positive allosteric modulators at these receptors, increasing the frequency of chloride channel opening in response to endogenous GABA. With prolonged exposure, the receptor complex adapts: subunit composition shifts, receptor density decreases, and the magnitude of response to a given benzodiazepine dose falls. The clinical result is that the dose that produced the original anxiolytic or hypnotic effect stops producing it. The patient is now receiving the drug for a nervous system that has reshaped itself around it.

Recognizable Features

Tolerance withdrawal looks different from a straightforward relapse of the original condition, though the distinction is frequently missed in a brief clinic visit. Several features are characteristic.

Symptoms that were not present before the benzodiazepine was started. Patients often report new physical phenomena — perioral numbness, paresthesias, muscle twitching, inner tremor, photophobia, hyperacusis, gastrointestinal symptoms, tinnitus — that were absent at baseline and do not fit the original diagnosis.

Interdose symptoms with short-acting agents. Patients on alprazolam or lorazepam frequently describe a time-locked pattern: symptoms build through the interdose interval and are briefly relieved by the next dose. This is indistinguishable in form from a short-acting withdrawal course and essentially confirms tolerance.

Failure of dose increases to hold. A dose increase produces transient improvement, often only for a few weeks, before symptoms return at the new dose. The ladder keeps climbing without producing sustained relief.

Morning worsening. Overnight metabolism of the drug can produce a morning low point with agitation, anxiety, or physical symptoms that resolve an hour or two after the morning dose. The pattern is again time-locked to pharmacokinetics, not to the patient’s day.

Sensory sensitivity and autonomic features. Heightened startle, light or sound sensitivity, temperature dysregulation, and episodes of tachycardia are common and typically unrelated to the patient’s original presenting complaint.

Why This Is Usually Missed

The clinical problem is structural. A patient who presents with worsening anxiety on a long-term benzodiazepine prescription typically receives a dose increase or a second psychotropic. Neither intervention addresses tolerance. The dose increase buys a few weeks; the second agent (often an SSRI or a neuroleptic prescribed for sleep) adds new pharmacologic variables without resolving the underlying adaptation.

Two features of the standard office visit contribute. First, most prescribers have limited exposure to the tolerance literature; the framework is not a default diagnostic consideration for new anxiety complaints. Second, the symptom pattern overlaps genuinely with primary anxiety disorders, and a time-limited visit cannot easily distinguish a patient in tolerance withdrawal from a patient whose original condition is worsening. The prescription environment therefore drifts toward dose escalation and polypharmacy.

Clinical Implications for the Taper

Tolerance withdrawal changes what a taper means. A patient who is already in withdrawal on their current dose is not going to experience the first several reductions as introducing new symptoms; they are going to experience them against a baseline that already includes withdrawal features. This has several practical consequences.

The first is that a very slow initial pace is often better tolerated than a standard one. Patients in tolerance withdrawal frequently stabilize partially during the first weeks of a taper — paradoxical as that sounds — because stable receptor conditions begin to reassert themselves once the dose stops being a moving target.

The second is that interdose stabilization sometimes matters more than dose reduction, especially for short-acting agents. Switching a patient from alprazolam to an equivalent dose of a longer-acting benzodiazepine such as diazepam (the Ashton substitution) can reduce interdose symptoms and make subsequent dose reductions more tolerable. This is not always the right move — the Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) refine the Ashton substitution and treat it as one tool rather than a universal step — but it is worth considering early.

The third is that treating tolerance withdrawal as if it were an indication for dose increase is actively harmful. The reflex to add dose, or to add another medication, when a patient on a long-term benzodiazepine develops new symptoms is, in this population, the step that produces the most downstream harm. Recognizing tolerance as a possibility changes the conversation from “how much more do we add” to “how do we unwind this safely.”

What Patients Can Bring to a Visit

For patients who suspect they are in tolerance, several things help at the prescriber visit.

A symptom timeline: when each symptom first appeared, in relation to starting or increasing the benzodiazepine or to dose timing within the day. Handwritten is fine; dated is essential.

A dose history: drug, dose, frequency, and any escalations over time.

The specific concern framed as tolerance, not relapse. “These symptoms are new and time-locked to dosing” is a different clinical question from “my anxiety is worse.”

A willingness to discuss a taper. Many prescribers will not initiate the tolerance conversation, but most will engage with it if the patient raises the possibility directly.

Tolerance withdrawal is not a rare presentation. It is common, under-recognized, and the most reliable predictor of the patients who arrive later in protracted withdrawal with symptoms that have been accumulating for years. Identifying it early is the single intervention most likely to change the trajectory.